Goldman Sachs analyst Scott Fidel lowered the firm’s price target on Molina Healthcare (MOH) to $167 from $207 and keeps a Neutral rating on the shares. The company reported a Q3 earnings miss and lowered its 2025 outlook as the “downslope” in the government-sponsored underwriting cycle drove further margin compression, the analyst tells investors in a research note. The firm sees investors debating Molina’s “relative optimism” on Medicaid margins in 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MOH:
- Molina Healthcare price target lowered to $165 from $203 at Deutsche Bank
- Molina Healthcare downgraded to Underweight from Equal Weight at Barclays
- Molina Healthcare’s Q3 2025 Financial Performance Overview
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
- Molina Healthcare falls -21.1%